DianaMarinaBrainardMD
Infectious Disease • Boston, MAVice President, Clinical Research at Gilead Sciences
Are you Dr. Brainard?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 57 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Boston, MA 02114Phone+1 617-724-9060Fax+1 617-726-5411- Is this information wrong?
Summary
- Dr. Diana Brainard, MD is an infectious disease specialist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is a Vice President at Clinical Research at Gilead Sciences.
Education & Training
Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2001 - 2004- Massachusetts General HospitalResidency, Internal Medicine, 1997 - 2000
Tulane University School of MedicineClass of 1997
Certifications & Licensure
MA State Medical License 1999 - 2012
Clinical Trials
- A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C Start of enrollment: 2010 Aug 01
- A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment Start of enrollment: 2013 Mar 01
Publications & Presentations
PubMed
- 33 citationsVesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.Sharon A. Riddler, Michael F. Para, Constance A. Benson, Anthony Mills, Moti Ramgopal, Edwin DeJesus, Cynthia Brinson, Joshua C. Cyktor, Jana L. Jacobs, Dianna Koontz,...> ;Clinical Infectious Diseases. 2021 Jun 1
- 22 citationsSofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-r...Eric Lawitz, Charles S. Landis, Maurizio Bonacini, Grisell Ortiz-Lasanta, Jonathan Huang, Jie Zhang, Brian Kirby, Shampa De-Oertel, Robert H. Hyland, Anu Osinusi, Dian...> ;The Lancet. Gastroenterology & Hepatology. 2020 Oct 1
- 360 citationsWeight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical TrialsPaul E. Sax, Kristine M. Erlandson, Jordan E. Lake, Grace A. McComsey, Chloe Orkin, Stefan Esser, Todd T. Brown, Jürgen K. Rockstroh, Xuelian Wei, Christoph C Carter, ...> ;Clinical Infectious Diseases. 2020 Sep 12
- Join now to see all
Authored Content
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
- Join now to see all
Press Mentions
AlloVir to Present at the BofA Securities 2023 Health Care ConferenceMay 1st, 2023- AlloVir Announces Positive Results in Oral Presentation at EBMT 2023, Including Long-Term Mortality Data from Phase 2 Posoleucel Multiviral Prevention StudyApril 26th, 2023
- AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023January 9th, 2023
- Join now to see all
Grant Support
- The Effects Of HIV GP120 On CTL Migration And EfficacyNational Institute Of Allergy And Infectious Diseases2004–2006
